Healthcare Industry News: antibody-drug conjugate
News Release - May 16, 2006
Seattle Genetics Names Pamela Trail, Ph.D., as Chief Scientific Officer
BOTHELL, Wash.--(HSMN NewsFeed)--May 16, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN ) announced today that Pamela A. Trail, Ph.D., a pharmaceutical industry veteran with almost 20 years of research and development experience, has joined the Company as its Chief Scientific Officer.Dr. Trail's career has focused on the discovery and preclinical development of monoclonal antibody-based cancer therapies. She joins Seattle Genetics from Bayer Healthcare where she spent more than five years, most recently as Vice President, Department of Protein Therapeutics. Previously, Dr. Trail worked for 14 years at Bristol-Myers Squibb Pharmaceutical Research Institute where she held various positions in Oncology Drug Discovery.
"Pam's extensive experience in developing targeted cancer therapeutics, coupled with her proven scientific leadership skills, will be a valuable asset to Seattle Genetics and a strong addition to our management team," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "She will play a key role in continuing the advancement of our product pipeline of engineered antibodies and antibody-drug conjugates. Pam will also guide our efforts in novel technologies and discovery of new molecules to fuel future pipeline growth."
In her position, Dr. Trail will be a member of the senior executive staff, overseeing the company's antibody technologies, chemistry and preclinical therapeutics groups. She will report to Clay Siegall, Ph.D., President and Chief Executive Officer.
"The strength of Seattle Genetics' product pipeline, together with its focus in oncology, makes this an exciting professional opportunity for me," said Dr. Trail. "I am very pleased to join the team and look forward to contributing to the development of the company's innovative therapeutics."
Dr. Trail holds more than 20 issued patents, has authored over 30 papers and is a member of both the American Association for Cancer Research and the American Society of Clinical Oncology. She received a B.S. in Biology/Microbology and a Ph.D. in Immunology and Virology from the University of Connecticut and conducted her postdoctoral research fellowship at the Memorial Sloan-Kettering Institute for Cancer Research.
About Seattle Genetics
Seattle Genetics is a biotechnology company focused on the development of monoclonal antibody-based therapies for the treatment of cancer and immunologic diseases. The company is conducting multiple clinical trials of its three lead product candidates, SGN-30, SGN-40 and SGN-33, and preclinical development of several late-stage programs, including SGN-35. In addition, Seattle Genetics has developed proprietary antibody-drug conjugate (ADC) technology comprised of highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. The company currently has license agreements for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Genentech, Bayer, CuraGen and MedImmune. More information about Seattle Genetics' pipeline and technologies can be found at www.seattlegenetics.com.
Certain of the statements made in this press release are forward-looking. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Specifically, statements regarding continued advancement of the company's product pipeline are forward-looking and actual results may differ materially from these statements for various reasons. Factors that may cause such a difference include risks related to adverse clinical results as our product candidates move into and advance in clinical trials. More information about the risks and uncertainties faced by Seattle Genetics is contained in the Company's filings with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Seattle Genetics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
